Press release
Animal Nutrition
May 17, 2022

Evonik published first edition of the MetAMINO® ATLAS

  • Performance trials investigating the relative nutritive value of DL-methionine vs. liquid MHA-FA and MHA-Ca
  • Support for knowledge-based purchase decisions for sustainable and economical livestock operations
  • Comparable achievements with 65 units of MetAMINO® vs. 100 units of MHA-products

Essen, Germany. Evonik has published the first edition of the MetAMINO® ATLAS. The report displays the results of 15 performance trials investigating the relative bioavailability of supplementary methionine sources in animal diets.

“For cost-effective purchasing, feed formulation and animal production, precise knowledge about the relative nutritive value of DL-methionine compared with liquid MHA-FA and MHA-Ca is essential,” says Dr. Jan-Olaf Barth, head of the Efficient Nutrition product line at Evonik. “With the MetAMINO® ATLAS, we want to support our business partners in making knowledge-based purchase decisions for sustainable and economical livestock operations.”

The trials were conducted in eleven countries on five continents under different climatic, geographic and farm conditions - in experimental settings as well as at commercial farms with broiler chickens, laying hens, swine and aqua species.

“Across all trials and all species, we found that comparable animal performance criteria were achieved when 100 units of MHA- products were replaced with 65 units of MetAMINO®,” says Nils Niedner, product manager MetAMINO®.

The MetAMINO® ATLAS 2022 further includes a selection of latest scientific articles, conference abstracts and peer reviewed publications regarding the bio-efficacy of the commercially available methionine forms. Interested parties can access the complete paper via barcode or link.

It can be downloaded under

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15 billion and an operating profit (adjusted EBITDA) of €2.38 billion in 2021. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.56 billion in 2021 with about 5,300 employees.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.